On March 28, 2025, Mangoceuticals, Inc. converted 392 shares of Series B Convertible Preferred Stock into 287,467 shares of common stock at a conversion price of $1.50 per share, totaling an aggregate value of $431,200. The company claims an exemption from registration for this transaction under the Securities Act.